In recent years, it has become clear that women and men may differ for drug response. Also, there is an increasing recognition on the role of sex hormones on pharmacokinetics and pharmacodynamics as mechanism accounting for sex differences in drug effects.
In women, the phases of menstrual cycle, of reproductive life and fluctuations in the concentrations of sexual steroids on pharmacokinetics and pharmacodynamics must be considered. Furthermore, the use of oral contraceptives or hormonal replacement therapy, the sex hormone-related changes in total body water or in the amount of fat influence the overall effect of drugs.
On the contrary, the influence of androgens on drug effects is minimal because of the even plasma levels of these hormones in adult males.
Nevertheless, since women have been scarcely included in the early phases of clinical trials, the results obtained in men have been often translated to women and their exact response to drugs is still not well known.
The available evidence suggests that sex hormones influence drug absorption, distribution, metabolism, pharmacodynamics, and adverse effects. For instance, many cardiovascular drugs are metabolized by enzymes of the cytochrome P450 mono-oxygenases system, which is more expressed in females than in males, showing sex differences in drug response.
Upcoming pharmacological research should aim to further clarify the influence of sex hormones on drug effects and, for this purpose, to increase the number of women enrolled in all phases of clinical trials. An evidence-based pharmacotherapy in women is therefore auspicable for women’s health.
Pharmacokinetics Pharmacodynamics Sex Progesterone Estrogen Testosterone Drug adverse effects
Cytochrome P450 mono-oxygenases
Supported by a grant of the Italian Ministry of Health—Ministero della Salute, Ricerca Corrente 2011.
Anthony M (2005) Male/female differences in pharmacology: safety issues with QT-prolonging drugs. J Womens Health (Larchmt) 14:47–52CrossRefGoogle Scholar
Arias-Loza PA, Hu K, Dienesch C et al (2007) Both estrogen receptor subtypes, alpha and beta, attenuate cardiovascular remodeling in aldosterone salt-treated rats. Hypertension 50:432–438PubMedCrossRefGoogle Scholar
Boersma E, Harrington RA, Moliterno DJ et al (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359:189–198PubMedCrossRefGoogle Scholar
Custodio JM, Wu CY, Benet LZ (2008) Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 60:717–733PubMedCrossRefGoogle Scholar
De Silva TM, Broughton BR, Drummond GR et al (2009) Gender influences cerebral vascular responses to angiotensin II through Nox2-derived reactive oxygen species. Stroke 40:1091–1097PubMedCrossRefGoogle Scholar
Everson GT (1992) Gastrointestinal motility in pregnancy. Gastroenterol Clin North Am 21:751–776PubMedGoogle Scholar
Fischer M, Baessler A, Schunkert H (2002) Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 53:672–677PubMedCrossRefGoogle Scholar
Franconi F, Carru C, Malorni W et al (2011a) The effect of sex/gender on cardiovascular pharmacology. Curr Pharm Des 17:1095–1107PubMedGoogle Scholar
Franconi F, Sanna M, Straface E et al (2011b) Pharmacokinetics and pharmacodynamics: the role of sex and gender. In: Oertelt-Prigione S, Regitz-Zagrosek V (eds) Sex and Gender aspects in clinical medicine. Springer, LondonGoogle Scholar
Gandhi M, Aweeka F, Greenblatt RM et al (2004) Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44:499–523PubMedCrossRefGoogle Scholar
Gilmore DA, Gal J, Gerber JG et al (1992) Age and gender influence the stereoselective pharmacokinetics of propranolol. J Pharmacol Exp Ther 261:1181–1186PubMedGoogle Scholar
Hagg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169–173PubMedCrossRefGoogle Scholar
Hinojosa-Laborde C, Chapa I, Lange D et al (1999) Gender differences in sympathetic nervous system regulation. Clin Exp Pharmacol Physiol 26:122–126PubMedCrossRefGoogle Scholar
Jochmann N, Stangl K, Garbe E et al (2005) Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 26:1585–1595PubMedCrossRefGoogle Scholar
Johnson JA, Akers WS, Herring VL et al (2000) Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. Pharmacotherapy 20:622–628PubMedCrossRefGoogle Scholar
Krecic-Shepard ME, Barnas CR, Slimko J et al (2000) Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin Pharmacol Ther 68:286–292PubMedCrossRefGoogle Scholar
Kurokawa J, Suzuki T, Furukawa T (2009) New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: acute effects of female hormones on cardiac ion channels and cardiac repolarization. J Pharmacol Sci 109:334–340PubMedCrossRefGoogle Scholar
Leinwand LA (2003) Sex is a potent modifier of the cardiovascular system. J Clin Invest 112:302–307PubMedGoogle Scholar
Luzier AB, Killian A, Wilton JH et al (1999) Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 66:594–601PubMedGoogle Scholar
Malorni W, Campesi I, Straface E et al (2007) Redox features of the cell: a gender perspective. Antioxid Redox Signal 9:1779–1801PubMedCrossRefGoogle Scholar
Malorni W, Straface E, Matarrese P et al (2008) Redox state and gender differences in vascular smooth muscle cells. FEBS Lett 582:635–642PubMedCrossRefGoogle Scholar
Oertelt-Prigione S, Regitz-Zagrosek V (2009) Gender aspects in cardiovascular pharmacology. J Cardiovasc Transl Res 2:258–266PubMedCrossRefGoogle Scholar
Ostadal B, Netuka I, Maly J et al (2009) Gender differences in cardiac ischemic injury and protection–experimental aspects. Exp Biol Med (Maywood) 234:1011–1019CrossRefGoogle Scholar
Patel H, Bell D, Molokhia M et al (2007) Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005. BMC Clin Pharmacol 7:9PubMedCrossRefGoogle Scholar
Pirmohamed M, James S, Meakin S et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15–19PubMedCrossRefGoogle Scholar
Pretorius M, Luther JM, Murphey LJ et al (2005) Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men. Arterioscler Thromb Vasc Biol 25:2435–2440PubMedCrossRefGoogle Scholar
Qayyum R, Becker DM, Yanek LR et al (2008) Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol 101:1359–1363PubMedCrossRefGoogle Scholar
Rathore SS, Wang Y, Krumholz HM (2002) Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347:1403–1411PubMedCrossRefGoogle Scholar
Regitz-Zagrosek V (2006) Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 5:425–438PubMedCrossRefGoogle Scholar
Rosano GM, Leonardo F, Dicandia C et al (2000) Acute electrophysiologic effect of estradiol 17beta in menopausal women. Am J Cardiol 86(1385–7):A5–A6Google Scholar
Rosano GM, Leonardo F, Sarrel PM et al (1996) Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet 347:786–788PubMedCrossRefGoogle Scholar
Schwartz JB (2003a) Gender-specific implications for cardiovascular medication use in the elderly optimizing therapy for older women. Cardiol Rev 11:275–298PubMedCrossRefGoogle Scholar
Schwartz JB (2007) The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 82:87–96PubMedCrossRefGoogle Scholar
Shekelle PG, Rich MW, Morton SC et al (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41:1529–1538PubMedCrossRefGoogle Scholar
Singh S, Zoble RG, Yellen L et al (2000) Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 102:2385–2390PubMedCrossRefGoogle Scholar
Soldin OP, Mattison DR (2009) Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 48:143–157PubMedCrossRefGoogle Scholar